肾病和高血压

以下为当前的临床试验。

按院区、状态和其他条件筛选该研究列表。

1. Study to Evaluate Clinical Complications, Pattern of Kidney Function Decline and Identification of Clinical Variables Related to Progression of Autosomal Dominant Polycystic Kidney Disease

   Rochester, Minn.

   The purpose of this study is to evaluate clinical complications, pattern of kidney function decline and identification of clinical variables related to progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

2. A Study to Determine the Incidence of Atrial and Ventricular Arrhythmias in Patients with Hypertrophic Cardiomyopathy

   Rochester, Minn.

   The purpose of this study is to determine the incidence of atrial and ventricular arrhythmias in patients with hypertrophic cardiomyopathy, with and without sleep apnea.

3. Monogenic Kidney Stone - Genetic Testing

   Rochester, Minn.

   90 genes related to Monogenic Stone Disease will be determined via DNA analysis by the Mayo Rare Kidney Stone Consortium (RKSC) research staff.

4. Baxdrostat in Uncontrolled Hypertension on Two or More Medications Including Resistant Hypertension

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension).

5. A Study to Evaluate the Effectiveness and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients

   Rochester, Minn.

   The purpose of this study is to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have an active antibody mediated rejection (AMR) after recently been kidney transplanted. The purpose is also to investigate and compare safety for these two treatments. 20 patients will be treated with imlifidase and 10 with PE.

以下为当前的临床试验。

按院区、状态和其他条件筛选该研究列表。

1. Study to Evaluate Clinical Complications, Pattern of Kidney Function Decline and Identification of Clinical Variables Related to Progression of Autosomal Dominant Polycystic Kidney Disease

   Rochester, Minn.

   The purpose of this study is to evaluate clinical complications, pattern of kidney function decline and identification of clinical variables related to progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

2. Monogenic Kidney Stone - Genetic Testing

   Rochester, Minn.

   90 genes related to Monogenic Stone Disease will be determined via DNA analysis by the Mayo Rare Kidney Stone Consortium (RKSC) research staff.

3. A Study to Determine the Incidence of Atrial and Ventricular Arrhythmias in Patients with Hypertrophic Cardiomyopathy

   Rochester, Minn.

   The purpose of this study is to determine the incidence of atrial and ventricular arrhythmias in patients with hypertrophic cardiomyopathy, with and without sleep apnea.

4. Baxdrostat in Uncontrolled Hypertension on Two or More Medications Including Resistant Hypertension

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension).

5. A Study to Evaluate the Effectiveness and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients

   Rochester, Minn.

   The purpose of this study is to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have an active antibody mediated rejection (AMR) after recently been kidney transplanted. The purpose is also to investigate and compare safety for these two treatments. 20 patients will be treated with imlifidase and 10 with PE.